Archive for the ‘society journal retractions’ Category
We’ve previously reported on six retractions of papers co-authored by Yoshihiro Sato, who is based at Mitate Hospital in Japan, including one in JAMA. Retractions stemmed from the use of “honorary” co-authors, as well as concerns over the data. One paper seemed to be the victim of “extensive self-plagiarism.”
Sato, who is the first and corresponding author of all ten retractions (including the letter), accepted full responsibility of the newly retracted publications, noting that none of the co-authors took part in any misconduct.
The Canadian Institutes of Health Research (CIHR) has banned a bone researcher for life following a finding of misconduct. And in a first, the agency has named her, in their report out today.
The case of Sophie Jamal may be familiar to Retraction Watch readers, as we covered it in October of last year following reporting by The Toronto Star. JAMA retracted a 2011 study by Jamal and colleagues in December, as we reported, and resigned her positions at Women’s College Hospital (WCH) and the University of Toronto.
Jamal, according to the an investigating committee at WCH: Read the rest of this entry »
A former postdoctoral researcher at the University of Pittsburgh has issued his first retraction after an investigation by the Office of Research Integrity (ORI) concluded he had falsified and/or fabricated data in two published papers.
The ORI investigation into the work of Kenneth Walker, determined that he had
falsified and/or fabricated quantitative real-time polymerase chain reaction (qPCR) data to demonstrate a statistically significant or “trend” of statistical difference in the expression of renal or bladder urothelium and muscle developmental markers between control and experimental (mutant) mice, when there was none.
The ORI report said that Walker has agreed to retract or correct a 2013 PLOS ONE paper and a 2015 study published in American Journal of Physiology – Renal Physiology (AJPRP).
A vociferous advocate for correcting the literature — who has been banned by two publishers for his persistent communications — has asked journals to retract one paper and correct three others for duplications.
After a reader flagged his 2004 paper on PubPeer last month, author Jaime Teixeira da Silva “immediately” contacted the journal to alert it that the paper had been duplicated, as he noted on a recent comment on our site:
A research fellow at Harvard has lost his PhD from a university in Singapore after being found guilty of falsifying data, and his former group leader’s contract has been terminated by his institution.
But that’s not the whole story. This tangled mess involves not only the Harvard researcher, Sudarsanareddy Lokireddy, and his former boss, Ravi Kambadur at the Nanyang Technological University (NTU) in Singapore, but an as-yet unnamed colleague of theirs who, we’re told, has admitted making up data in three papers, on which Lokireddy and Kambadur are co-authors. Bear with us as we walk you through this tale.
Two of those papers have been retracted by The Journal of Biological Chemistry (JBC); one in Molecular Endocrinology has yet to be pulled. Kambadur, who held joint appointments at the NTU and the Agency for Science, Research and Technology (A*STAR) in Singapore, has now had his contract terminated at both institutions. Read the rest of this entry »
According to the ORI report issued on May 25, Ricky Malhotra, one of the researchers in question, admitted to fabricating 74 experiments, and falsifying well over 100 Western blots while at the Universities of Michigan (UM) and Chicago (UC). One week later, the ORI issued additional findings about Karen D’Souza, a colleague of Malhotra’s at the UC, concluding that she had also falsified some data.
Both researchers agreed to the retraction of a 2010 paper published in The Journal of Biological Chemistry (JBC), the reports note.
After a prominent researcher was dismissed due to multiple instances of misconduct in his studies, how are journals responding?
When an investigation by the U.S. Food and Drug Administration (FDA) found multiple issues with the work of psychiatry researcher Alexander Neumeister, New York University (NYU) Langone Medical Center shut down eight of his studies. (Disclosure: The author of this post is an NYU journalism student, but has no relationship with the medical school.) The agency concluded the studies, which involved using experimental drugs to relieve symptoms of post-traumatic stress disorder (PTSD), were tainted by lax oversight, falsified records, and inaccurate case histories, according to the New York Times. (Neuroskeptic also recently analyzed the case.)
We reached out to the journals that have published Neumeister’s papers, to ask if these recent events have caused them to take a second look at his work. Several have responded, with some noting they plan to investigate, or will do so if asked by the institution. But many believe there is little cause for concern. Read the rest of this entry »
A JAMA journal has quickly issued a correction for a 2016 paper after the author failed to mention several relevant conflicts of interest. Normally, we’d see this as a run-of-the-mill correction notice, but since we reported last week that a journal retracted a paper for omitting pharma funding, we got to wondering: Is failure to disclose a conflict of interest a retractable offense?
Guidelines from the Committee on Publication Ethics (COPE) do say that retractions are used for “failure to disclose a major competing interest likely to influence interpretations or recommendations.” But most of the time when we see corrections to the literature for such omissions, they’re corrections, not retractions.
On Friday, JAMA Ophthalmology issued a correction notice for an invited commentary published in April, which addressed two papers in the journal about melanoma of the eye (uveal melanoma). However, the original commentary failed to note that author Arun D. Singh at the Cleveland Clinic had some relevant conflicts to mention, as the notice explains: Read the rest of this entry »
An erstwhile cell biologist has retracted five papers published in the Journal of Cell Science (JCS), all of which had been flagged in a recent investigation by the U.S. Office of Research Integrity (ORI).
The probe identified eight papers co-authored by Pastorino, six of which had already received expressions of concern (EOC) — including all of the newly retracted JCS papers. Nataly Shulga is a co-author on all eight papers.
Last week, we reported on the first of the expected retractions of the flagged papers in the Journal of Biological Chemistry.
The paper explicitly noted that the authors do not have any financial conflicts of interest, and that a government program supported the study. According to the journal, a reader alerted them to the conflict of interest.
The cooperate tie wasn’t a secret, though — one of the authors was listed as affiliated with the company, Pharma Research Products, based in Korea.
Here’s the retraction notice for “A Phase III, Randomized, Double-Blind, Matched-Pairs, Active-Controlled Clinical Trial and Preclinical Animal Study to Compare the Durability, Efficacy and Safety between Polynucleotide Filler and Hyaluronic Acid Filler in the Correction of Crow’s Feet: A New Concept of Regenerative Filler:”